MMF
MMF is a pharmaceutical drug with 31 clinical trials. Currently 6 active trials ongoing. Historical success rate of 84.2%.
Success Metrics
Based on 16 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
10
Mid Stage
13
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
80.0%
16 of 20 finished
20.0%
4 ended early
6
trials recruiting
31
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Clinical Trials (31)
Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis
A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation
Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to Calcineurin Inhibitors
Allo HSCT Using RIC for Hematological Diseases
Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's Arteritis
Mycophenolate Mofetil in Gastrointestinal Henoch-Schonlein Purpura
Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
KidneyCare Immuno-optimization in Renal Allografts (KIRA)
Use of Baricitenib to Maintain of Remission
REduCing Immunogenicity to PegloticasE (RECIPE) Study
Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Combination Therapy of Severe Aplastic Anemia
Natural Killer Cells Reconstitution Kinetics Post Haploidentical Transplantation
ATG in HLA-matched Sibling HSCT as GVHD Prophylaxis
Efficacy, Tolerability and Safety of Early Introduction of Everolimus, Reduced Calcineurin Inhibitors and Early Steroid Elimination Compared to Standard CNI, Mycophenolate Mofetil and Steroid Regimen in Paediatric Renal Transplant Recipients
Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic Syndrome
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 31